Issued 2026-08-13 at $18.38 · now $18.42 (2026-08-13, +0.2% since)
Based on its own history, a month from the 2026-08-13 close, SRPT has typically landed between $12.83 and $23.67 — a range of −30.2% to +28.8% from the issuance price $18.38.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
4,975 overlapping 1 month windows · 2006-09-26 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($18.38) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where SRPT has typically landed a month from the 2026-08-13 close of $18.38 — the range is history, not a prediction.
- now $18.42 (+0.2%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $18.18 (-1.1%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $16.4–$19.96
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $12.83–$23.67
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2013-10-14 | −71.4% | −71.4% | +4.7% |
| 2016-01-07 | −70.3% | −70.3% | +0.0% |
| 2015-12-28 | −69.9% | −69.9% | +4.1% |
| 3 best | |||
| 2008-12-18 | +193.8% | +0.0% | +193.8% |
| 2012-07-23 | +191.3% | +0.0% | +193.6% |
| 2012-07-20 | +181.4% | −4.2% | +181.4% |
4,975 overlapping windows · 2006-09-26 – 2026-08-13 · not cherry-picked
Pending catalysts
- 2026-10-31 — Trial primary completion: Phase 3 primary completion: A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) (source, as of 2026-08-14)
- 2026-12-31 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy (source, as of 2026-08-14)
- 2027-05-31 — Trial primary completion: Phase 3 primary completion: A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD) (source, as of 2026-08-14)
- 2028-12-31 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: Study of SRP-1001 in Adult and Adolescent Participants With Facioscapulohumeral Muscular Dystrophy Type 1 (source, as of 2026-08-14)
- 2033-10-31 — Trial primary completion: Phase 3 primary completion: A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.